
Please try another search
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 330.3% in the past one-month time frame.
The stock gained after the company reported that it initiated first ever personalized medicine-based clinical trial, CHOICES, in European cystic fibrosis patients.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Proteostasis Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Proteostasis Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Another stock worth considering in the Medical - Biomedical and Genetics sector is Alkermes plc (NASDAQ:ALKS) which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PTI going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Macro factors have weighed on corporate dealmaking, but we spot some potential bellwether transactions across sectors From wrestling rings to steakhouse tables, consolidation...
Mobileye Global Inc (NASDAQ:MBLY), which develops autonomous driving (AD) and driver-assistance technologies, announced the pricing of its stock sale that will help its majority...
Shares of technology firms, along with digital communications and consumer discretionary stocks, are the US equity market leaders by a wide margin in 2023, based on a set of ETF...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.